The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acute Migraine Drugs Market Research Report 2025
Synopsis
The global market for Acute Migraine Drugs was valued at US$ 2420 million in the year 2024 and is projected to reach a revised size of US$ 3936 million by 2031, growing at a CAGR of 7.3% during the forecast period.
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Acute Migraine Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Migraine Drugs.
The Acute Migraine Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Acute Migraine Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Migraine Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J
Segment by Type
Triptans
NSAIDs
Others
Segment by Application
Hospital Pharmacies
Drug Stores
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Acute Migraine Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Acute Migraine Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global market for Acute Migraine Drugs was valued at US$ 2420 million in the year 2024 and is projected to reach a revised size of US$ 3936 million by 2031, growing at a CAGR of 7.3% during the forecast period.
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Acute Migraine Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Migraine Drugs.
The Acute Migraine Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Acute Migraine Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Migraine Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J
Segment by Type
Triptans
NSAIDs
Others
Segment by Application
Hospital Pharmacies
Drug Stores
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Acute Migraine Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Acute Migraine Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Acute Migraine Drugs Market Overview
1.1 Product Definition
1.2 Acute Migraine Drugs by Type
1.2.1 Global Acute Migraine Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Triptans
1.2.3 NSAIDs
1.2.4 Others
1.3 Acute Migraine Drugs by Application
1.3.1 Global Acute Migraine Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.4 Global Acute Migraine Drugs Market Size Estimates and Forecasts
1.4.1 Global Acute Migraine Drugs Revenue 2020-2031
1.4.2 Global Acute Migraine Drugs Sales 2020-2031
1.4.3 Global Acute Migraine Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Acute Migraine Drugs Market Competition by Manufacturers
2.1 Global Acute Migraine Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Acute Migraine Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Acute Migraine Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Acute Migraine Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Acute Migraine Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Acute Migraine Drugs, Product Type & Application
2.7 Global Key Manufacturers of Acute Migraine Drugs, Date of Enter into This Industry
2.8 Global Acute Migraine Drugs Market Competitive Situation and Trends
2.8.1 Global Acute Migraine Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Acute Migraine Drugs Players Market Share by Revenue
2.8.3 Global Acute Migraine Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Acute Migraine Drugs Market Scenario by Region
3.1 Global Acute Migraine Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Acute Migraine Drugs Sales by Region: 2020-2031
3.2.1 Global Acute Migraine Drugs Sales by Region: 2020-2025
3.2.2 Global Acute Migraine Drugs Sales by Region: 2026-2031
3.3 Global Acute Migraine Drugs Revenue by Region: 2020-2031
3.3.1 Global Acute Migraine Drugs Revenue by Region: 2020-2025
3.3.2 Global Acute Migraine Drugs Revenue by Region: 2026-2031
3.4 North America Acute Migraine Drugs Market Facts & Figures by Country
3.4.1 North America Acute Migraine Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Acute Migraine Drugs Sales by Country (2020-2031)
3.4.3 North America Acute Migraine Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Acute Migraine Drugs Market Facts & Figures by Country
3.5.1 Europe Acute Migraine Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Acute Migraine Drugs Sales by Country (2020-2031)
3.5.3 Europe Acute Migraine Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Acute Migraine Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Acute Migraine Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Acute Migraine Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Acute Migraine Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Acute Migraine Drugs Market Facts & Figures by Country
3.7.1 Latin America Acute Migraine Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Acute Migraine Drugs Sales by Country (2020-2031)
3.7.3 Latin America Acute Migraine Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Acute Migraine Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Acute Migraine Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Acute Migraine Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Acute Migraine Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Acute Migraine Drugs Sales by Type (2020-2031)
4.1.1 Global Acute Migraine Drugs Sales by Type (2020-2025)
4.1.2 Global Acute Migraine Drugs Sales by Type (2026-2031)
4.1.3 Global Acute Migraine Drugs Sales Market Share by Type (2020-2031)
4.2 Global Acute Migraine Drugs Revenue by Type (2020-2031)
4.2.1 Global Acute Migraine Drugs Revenue by Type (2020-2025)
4.2.2 Global Acute Migraine Drugs Revenue by Type (2026-2031)
4.2.3 Global Acute Migraine Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Acute Migraine Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Acute Migraine Drugs Sales by Application (2020-2031)
5.1.1 Global Acute Migraine Drugs Sales by Application (2020-2025)
5.1.2 Global Acute Migraine Drugs Sales by Application (2026-2031)
5.1.3 Global Acute Migraine Drugs Sales Market Share by Application (2020-2031)
5.2 Global Acute Migraine Drugs Revenue by Application (2020-2031)
5.2.1 Global Acute Migraine Drugs Revenue by Application (2020-2025)
5.2.2 Global Acute Migraine Drugs Revenue by Application (2026-2031)
5.2.3 Global Acute Migraine Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Acute Migraine Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Acute Migraine Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GSK Acute Migraine Drugs Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Teva
6.2.1 Teva Company Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Acute Migraine Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Teva Acute Migraine Drugs Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Acute Migraine Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Acute Migraine Drugs Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Acute Migraine Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Acute Migraine Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Sun Pharma
6.5.1 Sun Pharma Company Information
6.5.2 Sun Pharma Description and Business Overview
6.5.3 Sun Pharma Acute Migraine Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sun Pharma Acute Migraine Drugs Product Portfolio
6.5.5 Sun Pharma Recent Developments/Updates
6.6 Grunenthal
6.6.1 Grunenthal Company Information
6.6.2 Grunenthal Description and Business Overview
6.6.3 Grunenthal Acute Migraine Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Grunenthal Acute Migraine Drugs Product Portfolio
6.6.5 Grunenthal Recent Developments/Updates
6.7 Endo Pharmaceuticals
6.7.1 Endo Pharmaceuticals Company Information
6.7.2 Endo Pharmaceuticals Description and Business Overview
6.7.3 Endo Pharmaceuticals Acute Migraine Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Endo Pharmaceuticals Acute Migraine Drugs Product Portfolio
6.7.5 Endo Pharmaceuticals Recent Developments/Updates
6.8 Merck
6.8.1 Merck Company Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck Acute Migraine Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Merck Acute Migraine Drugs Product Portfolio
6.8.5 Merck Recent Developments/Updates
6.9 J & J
6.9.1 J & J Company Information
6.9.2 J & J Description and Business Overview
6.9.3 J & J Acute Migraine Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 J & J Acute Migraine Drugs Product Portfolio
6.9.5 J & J Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Acute Migraine Drugs Industry Chain Analysis
7.2 Acute Migraine Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Acute Migraine Drugs Production Mode & Process Analysis
7.4 Acute Migraine Drugs Sales and Marketing
7.4.1 Acute Migraine Drugs Sales Channels
7.4.2 Acute Migraine Drugs Distributors
7.5 Acute Migraine Drugs Customer Analysis
8 Acute Migraine Drugs Market Dynamics
8.1 Acute Migraine Drugs Industry Trends
8.2 Acute Migraine Drugs Market Drivers
8.3 Acute Migraine Drugs Market Challenges
8.4 Acute Migraine Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Acute Migraine Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Acute Migraine Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Acute Migraine Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Acute Migraine Drugs Sales (K Unit) of Key Manufacturers (2020-2025)
Table 5. Global Acute Migraine Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Acute Migraine Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Acute Migraine Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Acute Migraine Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Acute Migraine Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Acute Migraine Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Acute Migraine Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Acute Migraine Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Acute Migraine Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Migraine Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Acute Migraine Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Acute Migraine Drugs Sales by Region (2020-2025) & (K Unit)
Table 18. Global Acute Migraine Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Acute Migraine Drugs Sales by Region (2026-2031) & (K Unit)
Table 20. Global Acute Migraine Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Acute Migraine Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Acute Migraine Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Acute Migraine Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Acute Migraine Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Acute Migraine Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Acute Migraine Drugs Sales by Country (2020-2025) & (K Unit)
Table 27. North America Acute Migraine Drugs Sales by Country (2026-2031) & (K Unit)
Table 28. North America Acute Migraine Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Acute Migraine Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Acute Migraine Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Acute Migraine Drugs Sales by Country (2020-2025) & (K Unit)
Table 32. Europe Acute Migraine Drugs Sales by Country (2026-2031) & (K Unit)
Table 33. Europe Acute Migraine Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Acute Migraine Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Acute Migraine Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Acute Migraine Drugs Sales by Region (2020-2025) & (K Unit)
Table 37. Asia Pacific Acute Migraine Drugs Sales by Region (2026-2031) & (K Unit)
Table 38. Asia Pacific Acute Migraine Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Acute Migraine Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Acute Migraine Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Acute Migraine Drugs Sales by Country (2020-2025) & (K Unit)
Table 42. Latin America Acute Migraine Drugs Sales by Country (2026-2031) & (K Unit)
Table 43. Latin America Acute Migraine Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Acute Migraine Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Acute Migraine Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Acute Migraine Drugs Sales by Country (2020-2025) & (K Unit)
Table 47. Middle East and Africa Acute Migraine Drugs Sales by Country (2026-2031) & (K Unit)
Table 48. Middle East and Africa Acute Migraine Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Acute Migraine Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Acute Migraine Drugs Sales (K Unit) by Type (2020-2025)
Table 51. Global Acute Migraine Drugs Sales (K Unit) by Type (2026-2031)
Table 52. Global Acute Migraine Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Acute Migraine Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Acute Migraine Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Acute Migraine Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Acute Migraine Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Acute Migraine Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Acute Migraine Drugs Price (USD/Unit) by Type (2020-2025)
Table 59. Global Acute Migraine Drugs Price (USD/Unit) by Type (2026-2031)
Table 60. Global Acute Migraine Drugs Sales (K Unit) by Application (2020-2025)
Table 61. Global Acute Migraine Drugs Sales (K Unit) by Application (2026-2031)
Table 62. Global Acute Migraine Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Acute Migraine Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Acute Migraine Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Acute Migraine Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Acute Migraine Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Acute Migraine Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Acute Migraine Drugs Price (USD/Unit) by Application (2020-2025)
Table 69. Global Acute Migraine Drugs Price (USD/Unit) by Application (2026-2031)
Table 70. GSK Company Information
Table 71. GSK Description and Business Overview
Table 72. GSK Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. GSK Acute Migraine Drugs Product
Table 74. GSK Recent Developments/Updates
Table 75. Teva Company Information
Table 76. Teva Description and Business Overview
Table 77. Teva Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Teva Acute Migraine Drugs Product
Table 79. Teva Recent Developments/Updates
Table 80. Pfizer Company Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Pfizer Acute Migraine Drugs Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Novartis Company Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Novartis Acute Migraine Drugs Product
Table 89. Novartis Recent Developments/Updates
Table 90. Sun Pharma Company Information
Table 91. Sun Pharma Description and Business Overview
Table 92. Sun Pharma Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Sun Pharma Acute Migraine Drugs Product
Table 94. Sun Pharma Recent Developments/Updates
Table 95. Grunenthal Company Information
Table 96. Grunenthal Description and Business Overview
Table 97. Grunenthal Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Grunenthal Acute Migraine Drugs Product
Table 99. Grunenthal Recent Developments/Updates
Table 100. Endo Pharmaceuticals Company Information
Table 101. Endo Pharmaceuticals Description and Business Overview
Table 102. Endo Pharmaceuticals Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Endo Pharmaceuticals Acute Migraine Drugs Product
Table 104. Endo Pharmaceuticals Recent Developments/Updates
Table 105. Merck Company Information
Table 106. Merck Description and Business Overview
Table 107. Merck Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Merck Acute Migraine Drugs Product
Table 109. Merck Recent Developments/Updates
Table 110. J & J Company Information
Table 111. J & J Description and Business Overview
Table 112. J & J Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. J & J Acute Migraine Drugs Product
Table 114. J & J Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Acute Migraine Drugs Distributors List
Table 118. Acute Migraine Drugs Customers List
Table 119. Acute Migraine Drugs Market Trends
Table 120. Acute Migraine Drugs Market Drivers
Table 121. Acute Migraine Drugs Market Challenges
Table 122. Acute Migraine Drugs Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Product Picture of Acute Migraine Drugs
Figure 2. Global Acute Migraine Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Acute Migraine Drugs Market Share by Type: 2024 & 2031
Figure 4. Triptans Product Picture
Figure 5. NSAIDs Product Picture
Figure 6. Others Product Picture
Figure 7. Global Acute Migraine Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Acute Migraine Drugs Market Share by Application: 2024 & 2031
Figure 9. Hospital Pharmacies
Figure 10. Drug Stores
Figure 11. Global Acute Migraine Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Acute Migraine Drugs Market Size (2020-2031) & (US$ Million)
Figure 13. Global Acute Migraine Drugs Sales (2020-2031) & (K Unit)
Figure 14. Global Acute Migraine Drugs Average Price (USD/Unit) & (2020-2031)
Figure 15. Acute Migraine Drugs Report Years Considered
Figure 16. Acute Migraine Drugs Sales Share by Manufacturers in 2024
Figure 17. Global Acute Migraine Drugs Revenue Share by Manufacturers in 2024
Figure 18. Global 5 and 10 Largest Acute Migraine Drugs Players: Market Share by Revenue in Acute Migraine Drugs in 2024
Figure 19. Acute Migraine Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 20. Global Acute Migraine Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 21. North America Acute Migraine Drugs Sales Market Share by Country (2020-2031)
Figure 22. North America Acute Migraine Drugs Revenue Market Share by Country (2020-2031)
Figure 23. U.S. Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 24. Canada Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Europe Acute Migraine Drugs Sales Market Share by Country (2020-2031)
Figure 26. Europe Acute Migraine Drugs Revenue Market Share by Country (2020-2031)
Figure 27. Germany Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. France Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. U.K. Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Italy Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Russia Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Asia Pacific Acute Migraine Drugs Sales Market Share by Region (2020-2031)
Figure 33. Asia Pacific Acute Migraine Drugs Revenue Market Share by Region (2020-2031)
Figure 34. China Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Japan Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. South Korea Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. India Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Australia Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Taiwan Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Indonesia Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Thailand Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Malaysia Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Philippines Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Acute Migraine Drugs Sales Market Share by Country (2020-2031)
Figure 45. Latin America Acute Migraine Drugs Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Acute Migraine Drugs Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Acute Migraine Drugs Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. UAE Acute Migraine Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Acute Migraine Drugs by Type (2020-2031)
Figure 55. Global Revenue Market Share of Acute Migraine Drugs by Type (2020-2031)
Figure 56. Global Acute Migraine Drugs Price (USD/Unit) by Type (2020-2031)
Figure 57. Global Sales Market Share of Acute Migraine Drugs by Application (2020-2031)
Figure 58. Global Revenue Market Share of Acute Migraine Drugs by Application (2020-2031)
Figure 59. Global Acute Migraine Drugs Price (USD/Unit) by Application (2020-2031)
Figure 60. Acute Migraine Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
